A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer
Background To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer (NSCLC). Methods Sensitizing mutation negative NSCLC patients with malignant pleural effusion were rand...
Gespeichert in:
| Veröffentlicht in: | Thoracic cancer 2020-01, Vol.11 (1), p.8-14 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 14 |
|---|---|
| container_issue | 1 |
| container_start_page | 8 |
| container_title | Thoracic cancer |
| container_volume | 11 |
| creator | Nie, Keke Zhang, Zhen You, Yunhong Zhuang, Xingjun Zhang, Chunling Ji, Youxin |
| description | Background
To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer (NSCLC).
Methods
Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24 hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72 hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed‐up.
Results
A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50 months and 3.70 months, respectively. The median serum VEGF level at 72 hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (P = 0.276). The median serum VEGF level at 72 hours decreased 52.02% compared to baseline level in patients’ DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (P = 0.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis.
Conclusions
Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion. |
| doi_str_mv | 10.1111/1759-7714.13238 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_proqu</sourceid><recordid>TN_cdi_proquest_miscellaneous_2315094454</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A737039345</galeid><doaj_id>oai_doaj_org_article_ed663cb83c404ad98d36a256eeb53ead</doaj_id><sourcerecordid>A737039345</sourcerecordid><originalsourceid>FETCH-LOGICAL-c6008-b6159001defc7b4d3983a907b00ad1166ef06be97730d4b38e85ef70badebfeb3</originalsourceid><addsrcrecordid>eNqNks1u1DAQxyMEolXpmRuKxAUJ7daOEye5IK1WfFSqxKWcLX9Mdr1K7MVOWm1PPAIvxYvwJEya7dJFSOAcnMz85u_M-J8kLymZU1wXtCzqWVnSfE5Zxqonyekh8vTwTvhJch7jhuBiVU2y4nlywmiZ8bwmp8mPRRqkM76zd2BS3VpntWzT2A9ml_Y-1b7bygCpdX2Q2xaGgFnrmiFa79Jb26-n1A04P8TfGd-kCm6ktndDJxXG034NaSedXEEHrh-BTrZ25SR-PAhDsy9Hfit7i2CcDnHe_fz2PWJJi7uGtk3bwa1SLZ2G8CJ51sg2wvl-P0u-fHh_vfw0u_r88XK5uJppTkg1U5wWNSHUQKNLlRtWV0zWpFSESEMp59AQrqAuS0ZMrlgFVQFNSZQ0oBpQ7Cy5nHSNlxuxDbaTYSe8tOI-4MNKyNBb3YIAwznTqmI6J7k0dWUYl1nBAVTBQBrUejdpbQfVgdEwjrE9Ej3OOLsWK38jeM2qMs9R4M1eIPivA8RedDaOk5EO8C5ExmhB6jwvRvT1H-jGD8HhqJBilFc8yx5RK4kN4FV6PFePomJRspKwmuUFUvO_UPgY6Kz2DhqL8aOCi6lABx9jgObQIyViNLIYrSpG24p7I2PFq8ejOfAPtkWgmoBbUL6JGo2i4YCh0_Oa4-XS0fR0aXu0kndLP7geS9_-fynSxZ7Gpnb_-nFxvVxMHfwCYrIk1A</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2331686224</pqid></control><display><type>article</type><title>A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>Wiley-Blackwell Open Access Titles</source><source>Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" /></source><source>Wiley Online Library All Journals</source><source>PubMed Central</source><creator>Nie, Keke ; Zhang, Zhen ; You, Yunhong ; Zhuang, Xingjun ; Zhang, Chunling ; Ji, Youxin</creator><creatorcontrib>Nie, Keke ; Zhang, Zhen ; You, Yunhong ; Zhuang, Xingjun ; Zhang, Chunling ; Ji, Youxin</creatorcontrib><description>Background
To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer (NSCLC).
Methods
Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24 hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72 hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed‐up.
Results
A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50 months and 3.70 months, respectively. The median serum VEGF level at 72 hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (P = 0.276). The median serum VEGF level at 72 hours decreased 52.02% compared to baseline level in patients’ DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (P = 0.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis.
Conclusions
Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion.</description><identifier>ISSN: 1759-7706</identifier><identifier>EISSN: 1759-7714</identifier><identifier>DOI: 10.1111/1759-7714.13238</identifier><identifier>PMID: 31726490</identifier><language>eng</language><publisher>Melbourne: John Wiley & Sons Australia, Ltd</publisher><subject>Angiogenesis ; Antineoplastic Agents, Immunological - administration & dosage ; Apoptosis ; Bevacizumab ; Bevacizumab - administration & dosage ; Cancer therapies ; Carcinoma, Non-Small-Cell Lung - drug therapy ; Carcinoma, Non-Small-Cell Lung - pathology ; Care and treatment ; Catheters ; Cell adhesion & migration ; Clinical trials ; CT imaging ; Disease ; Endothelium ; Equivalence Trials as Topic ; Female ; Follow-Up Studies ; Humans ; Immunotherapy ; Infusions, Intravenous ; Infusions, Parenteral ; Life Sciences & Biomedicine ; Lung cancer ; Lung cancer, Non-small cell ; Lung cancer, Small cell ; Lung Neoplasms - drug therapy ; Lung Neoplasms - pathology ; Male ; malignant pleural effusion ; Medical imaging ; Medical prognosis ; Metastasis ; Middle Aged ; Monoclonal antibodies ; non‐small‐cell lung cancer ; Oncology ; Original ; Patients ; Permeability ; Pleural Effusion, Malignant - drug therapy ; Pleural Effusion, Malignant - pathology ; Pleural effusions ; Prognosis ; Quality of life ; Respiratory System ; Response rates ; Science & Technology ; Targeted cancer therapy ; Ultrasonic imaging ; Vascular endothelial growth factor</subject><ispartof>Thoracic cancer, 2020-01, Vol.11 (1), p.8-14</ispartof><rights>2019 The Authors. published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd</rights><rights>2019 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.</rights><rights>COPYRIGHT 2020 John Wiley & Sons, Inc.</rights><rights>2020. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>true</woscitedreferencessubscribed><woscitedreferencescount>17</woscitedreferencescount><woscitedreferencesoriginalsourcerecordid>wos000496398100001</woscitedreferencesoriginalsourcerecordid><citedby>FETCH-LOGICAL-c6008-b6159001defc7b4d3983a907b00ad1166ef06be97730d4b38e85ef70badebfeb3</citedby><cites>FETCH-LOGICAL-c6008-b6159001defc7b4d3983a907b00ad1166ef06be97730d4b38e85ef70badebfeb3</cites><orcidid>0000-0003-2303-8784 ; 0000-0002-9311-0000</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938744/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6938744/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,315,728,781,785,865,886,1418,2103,2115,11567,27929,27930,28253,45579,45580,46057,46481,53796,53798</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/31726490$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Nie, Keke</creatorcontrib><creatorcontrib>Zhang, Zhen</creatorcontrib><creatorcontrib>You, Yunhong</creatorcontrib><creatorcontrib>Zhuang, Xingjun</creatorcontrib><creatorcontrib>Zhang, Chunling</creatorcontrib><creatorcontrib>Ji, Youxin</creatorcontrib><title>A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer</title><title>Thoracic cancer</title><addtitle>THORAC CANCER</addtitle><addtitle>Thorac Cancer</addtitle><description>Background
To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer (NSCLC).
Methods
Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24 hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72 hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed‐up.
Results
A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50 months and 3.70 months, respectively. The median serum VEGF level at 72 hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (P = 0.276). The median serum VEGF level at 72 hours decreased 52.02% compared to baseline level in patients’ DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (P = 0.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis.
Conclusions
Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion.</description><subject>Angiogenesis</subject><subject>Antineoplastic Agents, Immunological - administration & dosage</subject><subject>Apoptosis</subject><subject>Bevacizumab</subject><subject>Bevacizumab - administration & dosage</subject><subject>Cancer therapies</subject><subject>Carcinoma, Non-Small-Cell Lung - drug therapy</subject><subject>Carcinoma, Non-Small-Cell Lung - pathology</subject><subject>Care and treatment</subject><subject>Catheters</subject><subject>Cell adhesion & migration</subject><subject>Clinical trials</subject><subject>CT imaging</subject><subject>Disease</subject><subject>Endothelium</subject><subject>Equivalence Trials as Topic</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Humans</subject><subject>Immunotherapy</subject><subject>Infusions, Intravenous</subject><subject>Infusions, Parenteral</subject><subject>Life Sciences & Biomedicine</subject><subject>Lung cancer</subject><subject>Lung cancer, Non-small cell</subject><subject>Lung cancer, Small cell</subject><subject>Lung Neoplasms - drug therapy</subject><subject>Lung Neoplasms - pathology</subject><subject>Male</subject><subject>malignant pleural effusion</subject><subject>Medical imaging</subject><subject>Medical prognosis</subject><subject>Metastasis</subject><subject>Middle Aged</subject><subject>Monoclonal antibodies</subject><subject>non‐small‐cell lung cancer</subject><subject>Oncology</subject><subject>Original</subject><subject>Patients</subject><subject>Permeability</subject><subject>Pleural Effusion, Malignant - drug therapy</subject><subject>Pleural Effusion, Malignant - pathology</subject><subject>Pleural effusions</subject><subject>Prognosis</subject><subject>Quality of life</subject><subject>Respiratory System</subject><subject>Response rates</subject><subject>Science & Technology</subject><subject>Targeted cancer therapy</subject><subject>Ultrasonic imaging</subject><subject>Vascular endothelial growth factor</subject><issn>1759-7706</issn><issn>1759-7714</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>24P</sourceid><sourceid>WIN</sourceid><sourceid>AOWDO</sourceid><sourceid>EIF</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><sourceid>DOA</sourceid><recordid>eNqNks1u1DAQxyMEolXpmRuKxAUJ7daOEye5IK1WfFSqxKWcLX9Mdr1K7MVOWm1PPAIvxYvwJEya7dJFSOAcnMz85u_M-J8kLymZU1wXtCzqWVnSfE5Zxqonyekh8vTwTvhJch7jhuBiVU2y4nlywmiZ8bwmp8mPRRqkM76zd2BS3VpntWzT2A9ml_Y-1b7bygCpdX2Q2xaGgFnrmiFa79Jb26-n1A04P8TfGd-kCm6ktndDJxXG034NaSedXEEHrh-BTrZ25SR-PAhDsy9Hfit7i2CcDnHe_fz2PWJJi7uGtk3bwa1SLZ2G8CJ51sg2wvl-P0u-fHh_vfw0u_r88XK5uJppTkg1U5wWNSHUQKNLlRtWV0zWpFSESEMp59AQrqAuS0ZMrlgFVQFNSZQ0oBpQ7Cy5nHSNlxuxDbaTYSe8tOI-4MNKyNBb3YIAwznTqmI6J7k0dWUYl1nBAVTBQBrUejdpbQfVgdEwjrE9Ej3OOLsWK38jeM2qMs9R4M1eIPivA8RedDaOk5EO8C5ExmhB6jwvRvT1H-jGD8HhqJBilFc8yx5RK4kN4FV6PFePomJRspKwmuUFUvO_UPgY6Kz2DhqL8aOCi6lABx9jgObQIyViNLIYrSpG24p7I2PFq8ejOfAPtkWgmoBbUL6JGo2i4YCh0_Oa4-XS0fR0aXu0kndLP7geS9_-fynSxZ7Gpnb_-nFxvVxMHfwCYrIk1A</recordid><startdate>202001</startdate><enddate>202001</enddate><creator>Nie, Keke</creator><creator>Zhang, Zhen</creator><creator>You, Yunhong</creator><creator>Zhuang, Xingjun</creator><creator>Zhang, Chunling</creator><creator>Ji, Youxin</creator><general>John Wiley & Sons Australia, Ltd</general><general>Wiley</general><general>John Wiley & Sons, Inc</general><scope>24P</scope><scope>WIN</scope><scope>AOWDO</scope><scope>BLEPL</scope><scope>DTL</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><orcidid>https://orcid.org/0000-0003-2303-8784</orcidid><orcidid>https://orcid.org/0000-0002-9311-0000</orcidid></search><sort><creationdate>202001</creationdate><title>A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer</title><author>Nie, Keke ; Zhang, Zhen ; You, Yunhong ; Zhuang, Xingjun ; Zhang, Chunling ; Ji, Youxin</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c6008-b6159001defc7b4d3983a907b00ad1166ef06be97730d4b38e85ef70badebfeb3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Angiogenesis</topic><topic>Antineoplastic Agents, Immunological - administration & dosage</topic><topic>Apoptosis</topic><topic>Bevacizumab</topic><topic>Bevacizumab - administration & dosage</topic><topic>Cancer therapies</topic><topic>Carcinoma, Non-Small-Cell Lung - drug therapy</topic><topic>Carcinoma, Non-Small-Cell Lung - pathology</topic><topic>Care and treatment</topic><topic>Catheters</topic><topic>Cell adhesion & migration</topic><topic>Clinical trials</topic><topic>CT imaging</topic><topic>Disease</topic><topic>Endothelium</topic><topic>Equivalence Trials as Topic</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Humans</topic><topic>Immunotherapy</topic><topic>Infusions, Intravenous</topic><topic>Infusions, Parenteral</topic><topic>Life Sciences & Biomedicine</topic><topic>Lung cancer</topic><topic>Lung cancer, Non-small cell</topic><topic>Lung cancer, Small cell</topic><topic>Lung Neoplasms - drug therapy</topic><topic>Lung Neoplasms - pathology</topic><topic>Male</topic><topic>malignant pleural effusion</topic><topic>Medical imaging</topic><topic>Medical prognosis</topic><topic>Metastasis</topic><topic>Middle Aged</topic><topic>Monoclonal antibodies</topic><topic>non‐small‐cell lung cancer</topic><topic>Oncology</topic><topic>Original</topic><topic>Patients</topic><topic>Permeability</topic><topic>Pleural Effusion, Malignant - drug therapy</topic><topic>Pleural Effusion, Malignant - pathology</topic><topic>Pleural effusions</topic><topic>Prognosis</topic><topic>Quality of life</topic><topic>Respiratory System</topic><topic>Response rates</topic><topic>Science & Technology</topic><topic>Targeted cancer therapy</topic><topic>Ultrasonic imaging</topic><topic>Vascular endothelial growth factor</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Nie, Keke</creatorcontrib><creatorcontrib>Zhang, Zhen</creatorcontrib><creatorcontrib>You, Yunhong</creatorcontrib><creatorcontrib>Zhuang, Xingjun</creatorcontrib><creatorcontrib>Zhang, Chunling</creatorcontrib><creatorcontrib>Ji, Youxin</creatorcontrib><collection>Wiley-Blackwell Open Access Titles</collection><collection>Wiley Free Content</collection><collection>Web of Science - Science Citation Index Expanded - 2020</collection><collection>Web of Science Core Collection</collection><collection>Science Citation Index Expanded</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><jtitle>Thoracic cancer</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Nie, Keke</au><au>Zhang, Zhen</au><au>You, Yunhong</au><au>Zhuang, Xingjun</au><au>Zhang, Chunling</au><au>Ji, Youxin</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer</atitle><jtitle>Thoracic cancer</jtitle><stitle>THORAC CANCER</stitle><addtitle>Thorac Cancer</addtitle><date>2020-01</date><risdate>2020</risdate><volume>11</volume><issue>1</issue><spage>8</spage><epage>14</epage><pages>8-14</pages><issn>1759-7706</issn><eissn>1759-7714</eissn><abstract>Background
To compare the efficiency and toxicity of bevacizumab by intrapleural or intravenous infusion in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer (NSCLC).
Methods
Sensitizing mutation negative NSCLC patients with malignant pleural effusion were randomized into two groups in 1:1 ratio. The pleural effusion was completely drained in 24 hours; one group received intrapleural infusion and the second group received intravenous infusion of bevacizumab at a dose of 7.5 mg per kg bodyweight. The serum vascular endothelial growth factor (VEGF) was tested before and 72 hours after injection of bevacizumab. Computerized tomography (CT) scan to evaluate pleural effusions was carried out at four weeks for each patient and their survival followed‐up.
Results
A total of 67 patients were screened and 43 enrolled into the study. The response rate was 80% (16 of 20) in the intrapleural group and 66.7% (14 of 21) in the intravenous group. The median duration of response (DoR) of pleural effusion was 4.50 months and 3.70 months, respectively. The median serum VEGF level at 72 hours decreased 67.25% in the intrapleural group and 57.19% in the intravenous group compared to baseline level (P = 0.276). The median serum VEGF level at 72 hours decreased 52.02% compared to baseline level in patients’ DoR less than three months and 68.33% in patients' DoR longer than three months, respectively (P = 0.014). The main side effects noted were mild to moderate hypertension, proteinuria and epistaxis.
Conclusions
Bevacizumab intrapleural infusion had higher efficiency and higher safety than intravenous infusion in the management of malignant pleural effusion caused by NSCLC. The decreased level of serum VEGF at 72 hours after bevacizumab treatment was closely related to the response rate and duration of the response of pleural effusion.</abstract><cop>Melbourne</cop><pub>John Wiley & Sons Australia, Ltd</pub><pmid>31726490</pmid><doi>10.1111/1759-7714.13238</doi><tpages>7</tpages><orcidid>https://orcid.org/0000-0003-2303-8784</orcidid><orcidid>https://orcid.org/0000-0002-9311-0000</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1759-7706 |
| ispartof | Thoracic cancer, 2020-01, Vol.11 (1), p.8-14 |
| issn | 1759-7706 1759-7714 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2315094454 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; Wiley-Blackwell Open Access Titles; Web of Science - Science Citation Index Expanded - 2020<img src="https://exlibris-pub.s3.amazonaws.com/fromwos-v2.jpg" />; Wiley Online Library All Journals; PubMed Central |
| subjects | Angiogenesis Antineoplastic Agents, Immunological - administration & dosage Apoptosis Bevacizumab Bevacizumab - administration & dosage Cancer therapies Carcinoma, Non-Small-Cell Lung - drug therapy Carcinoma, Non-Small-Cell Lung - pathology Care and treatment Catheters Cell adhesion & migration Clinical trials CT imaging Disease Endothelium Equivalence Trials as Topic Female Follow-Up Studies Humans Immunotherapy Infusions, Intravenous Infusions, Parenteral Life Sciences & Biomedicine Lung cancer Lung cancer, Non-small cell Lung cancer, Small cell Lung Neoplasms - drug therapy Lung Neoplasms - pathology Male malignant pleural effusion Medical imaging Medical prognosis Metastasis Middle Aged Monoclonal antibodies non‐small‐cell lung cancer Oncology Original Patients Permeability Pleural Effusion, Malignant - drug therapy Pleural Effusion, Malignant - pathology Pleural effusions Prognosis Quality of life Respiratory System Response rates Science & Technology Targeted cancer therapy Ultrasonic imaging Vascular endothelial growth factor |
| title | A randomized clinical study to compare intrapleural infusion with intravenous infusion of bevacizumab in the management of malignant pleural effusion in patients with non‐small‐cell lung cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-14T06%3A01%3A11IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_proqu&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=A%20randomized%20clinical%20study%20to%20compare%20intrapleural%20infusion%20with%20intravenous%20infusion%20of%20bevacizumab%20in%20the%20management%20of%20malignant%20pleural%20effusion%20in%20patients%20with%20non%E2%80%90small%E2%80%90cell%20lung%20cancer&rft.jtitle=Thoracic%20cancer&rft.au=Nie,%20Keke&rft.date=2020-01&rft.volume=11&rft.issue=1&rft.spage=8&rft.epage=14&rft.pages=8-14&rft.issn=1759-7706&rft.eissn=1759-7714&rft_id=info:doi/10.1111/1759-7714.13238&rft_dat=%3Cgale_proqu%3EA737039345%3C/gale_proqu%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2331686224&rft_id=info:pmid/31726490&rft_galeid=A737039345&rft_doaj_id=oai_doaj_org_article_ed663cb83c404ad98d36a256eeb53ead&rfr_iscdi=true |